MedTrace Logo

Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations

NCT00347750 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-11-03

No results posted yet for this study

Summary

The objective of this proposal is based on the assumption that the HIV infected Ethiopian population responded in a different way in comparison to the Caucasian subjects to Lopinavir therapy. Our preliminary data demonstrated that Ethiopian's have different Lopinavir serum concentration in comparison to non-Ethiopian's. For these reasons the plan of this study is to investigate the pharmacokinetic/pharmacodynamic (PK/PD) profile in both populations. The results will allow to establish a better personalised medicine for HIV infected individuals.

Conditions

  • HIV Infection
  • AIDS

Interventions

DRUG

Lopinavir pharmacokinetic/pharmacodynamic analysis

Sponsors & Collaborators

  • Ministry of Health, Israel

    collaborator OTHER_GOV

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Norberto Krivoy, MD · Rambam Health Care Campus

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347750 on ClinicalTrials.gov